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Aim: The study aims to assess the a priori hypothesis that regular supplementation
with vitamin C or magnesium will permit a reduction in the corticosteroid dose
required to maintain asthma control in adults.
Methods: We invited all participants recruited from primary care centres who
completed a parallel-group, randomised, placebo-controlled, 16-week supplemen-
tation trial of 1 g/day vitamin C or 450mg/day magnesium to continue and
participate in a structured corticosteroid reduction protocol over 10 weeks.
Results: A total of 92 participants (29 vitamin C, 31 magnesium and 32 placebo)
entered the study. Assuming no reduction in corticosteroid dose in the 10 who
subsequently withdrew, the geometric mean reductions in inhaled corticosteroid
dose achieved with vitamin C, magnesium and placebo were 49, 13 and 11 mg,
respectively. Relative to placebo, the unadjusted effect of vitamin C was significant,
and remained at borderline significance after adjustment for baseline corticosteroid
dose (relative reduction ratio ¼ 4.03, 95% CI 0.95 to 17.1, P ¼ 0:06).
Conclusions: We conclude that while vitamin C supplements may have modest
corticosteroid sparing effects and hence the potential to reduce exposure to their
side effects, magnesium supplements have no effect on the inhaled corticosteroid
dose required to maintain asthma control.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Epidemiological evidence suggests that dietary
factors may have an important influence on the
incidence and severity of asthma,1 and both
vitamin C2,3 and magnesium3,4 are nutrients that
have been particularly implicated in this respect.
To date, several studies using short-term supple-
mentation with these agents have indicated that
they may be effective as therapies for asthma.5–9
However, with the exception of a placebo-con-
trolled study that reported a decrease in clinical
exacerbations of asthma during the Nigerian rainy
season after regular vitamin C supplements,10 there
is little evidence on the effects of longer-term
supplementation with either magnesium or vitamin
C. We have recently completed a double-blind,
placebo-controlled, parallel group intervention
study of 16 weeks vitamin C or magnesium
supplementation in 300 adults with a physician
diagnosis of asthma maintained on regular inhaled
corticosteroids, which found no evidence of an
effect on the clinical control of their disease.11 One
explanation for the discrepancy between our
negative intervention study and the observational
epidemiological studies suggesting an effect of
dietary vitamin C and magnesium intake on asthma
control is that participants in our study were adults
with asthma on regular inhaled corticosteroids.
This has resulted in a study population with good
asthma control as demonstrated by their low
baseline level of asthma symptoms, and hence
with only a small potential for improvement while
remaining on maintenance corticosteroid medica-
tion. At the end of this study, in accordance with
the original protocol, we invited participants to
continue with their allocated supplement for a
further 10 weeks, while undergoing a staged
corticosteroid reduction protocol to determine
whether either supplement had significant corti-
costeroid sparing effects. This was to see if there is
a beneficial effect of either supplement that was
masked by good asthma control attained by inhaled
corticosteroid therapy. We report the results of this
trial of the corticosteroid sparing effect of 26
weeks supplementation with vitamin C or magne-
sium in adults with asthma.Materials and methods
Study subjects
Men and women aged 18–60 with a physician
diagnosis of asthma who had been using at leastone dose of an inhaled corticosteroid daily for 6
months or more were identified from computerised
records in 24 General Practices in the Nottingham
area. Exclusion criteria were the current use of oral
corticosteroids or diuretics, use of vitamin C,
magnesium or calcium supplements in the past 3
months, an exacerbation of asthma requiring a
change in regular medication within the past 4
weeks, a cumulative smoking history of more than
10 pack years, current pregnancy or planned
pregnancy during the proposed trial period. Con-
senting individuals who met the entry criteria at an
initial screening visit were randomised to one of
the three study groups and entered a 3-week run-in
period in which they completed a daily record of
morning and evening peak flow measurements,
asthma symptom score and bronchodilator use.
Participants who did not satisfactorily complete
this asthma diary or had unstable asthma (defined
as any change in prophylactic medication use)
during the run-in period were excluded from
proceeding into the intervention period.Study design
The intervention study used a double-blind, rando-
mised, parallel-group, placebo-controlled design in
a two-phase study over a total of 26 weeks. In the
first phase we compared the effects of 16 weeks of
daily supplements with magnesium (450mg), vita-
min C (1 g) or placebo given in addition to regular
asthma medication, on the clinical control of
asthma. Participants were randomly assigned (using
a random number generator using blocks of nine
units) to one of the three treatment groups by
allocation of an individual code number, after the
first (screening) visit. The code for randomisation
was only broken after the final participant had left
the trial. All randomisation, tablet preparation and
dispensing were carried out independently from
the recruitment and assessment of participants and
were supervised by Sarah Pacey in Nottingham City
Hospital Pharmacy. This study, which has been
described and reported elsewhere, found no
evidence of benefit from either supplement.11Methods
For the current study, we invited all participants
completing the first phase to continue with their
allocated blinded supplement and enter a staged
inhaled corticosteroid reduction protocol adapted
from a previous investigation.12 The primary out-
come was the decrease in individual inhaled cortico-
steroid dose achieved in each active supplement
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sessed at 2-week intervals for a total of 10 weeks,
and on each occasion, in the absence of evidence of
deterioration in clinical control, were asked to
reduce their regular inhaled corticosteroid dose by
approximately 25% of their initial regular mainte-
nance dose. These incremental reductions in dose
were scaled to the baseline inhaled corticosteroid
dose in each individual, and designed to achieve
complete withdrawal of inhaled corticosteroids
within 8 weeks.
Deterioration in asthma control was defined as
one or more of:(1) an increase in average daily bronchodilator
usage by 6 or more inhalations over the 3 days
preceding the study visit,(2) a decrease in mean average morning and
evening peak flow over the 3 days preceding
the study visit of 15% or more below the
average values recorded during the 2 weeks
prior to the start of the steroid reduction
protocol,
’ ’(3) a positive response to the question are you
aware of any deterioration in your asthma?’’At each visit, participants who remained well
controlled were asked to reduce their inhaled
corticosteroid dose by the next planned increment.
Those who did not, either then or at any time
between visits, were asked to return and maintain
their inhaled corticosteroid dose at that at which
they had last felt well controlled, and remain on
that dose for the remainder of the study. The daily
dose of inhaled corticosteroid at the end of the
corticosteroid reduction stage (week 10 of the
present study, 26 weeks after starting the nutrient
supplements) was used as the final dose for analysis.Statistical analysis and power
The primary outcome was the decrease in individual
inhaled corticosteroid dose achieved in each active
supplement group relative to placebo. Reductions in
inhaled corticosteroid doses were normalised by
log10 transformation, after adding 1mg to all
reductions to remove zero values. All fluticasone
doses were doubled before transformation to reflect
the relative potency of this agent compared to
beclomethasone and budesonide.13 We compared
the reduction in corticosteroid in the vitamin C and
magnesium supplemented groups with placebo on an
intention-to-treat basis in all participants who
entered the steroid reduction phase, assuming no
reduction in all who withdrew, initially using t-tests,and then corrected for the baseline inhaled corticos-
teroid dose using analysis of covariance. All analyses
were carried out using the Statistical Package for the
Social Sciences (version 9.0). Our initial power
calculations were based on recruiting 300 partici-
pants to the first phase of the study, and assumed
that 240 of these would enter the corticosteroid
reduction phase of the study. This would have
provided 87% power to detect an increase in the
proportion of participants able to halve their inhaled
corticosteroid dose from 60% to 80%.Results
Of the 300 participants who entered the first phase
of supplementation (full details on recruitment and
compliance reported elsewhere11), 95 were rando-
mised to vitamin C, 99 to magnesium and 106 to
placebo. A total of 234 participants completed 16
weeks of supplementation, and of these, 92 (29
randomised to vitamin C, 31 to magnesium and 32
to placebo) consented to continue taking their
allocated supplements and enter the inhaled
corticosteroid reduction protocol. The treatment
groups were similar at baseline (Table 1), except
that baseline inhaled corticosteroid dose tended to
be higher in those receiving vitamin C supplements.
The main reason given for non-participation was
lack of time to complete a further five visits and
those who did not participate in the controlled
corticosteroid reduction had a slightly higher
requirement for inhaled corticosteroids compared
to those who did.
Ten participants (1 from the vitamin C group, 3
from magnesium and 6 from placebo) withdrew
from corticosteroid reduction, in most cases also
giving reasons relating to time. Assuming no
reduction in inhaled corticosteroids in these in-
dividuals, the geometric mean reductions in corti-
costeroid use achieved in the three groups were
equivalent to 49 (95% CI 18–132)mg beclometha-
sone/day with vitamin C, 13 (95% CI 5–38) mg with
magnesium and 11 (95% CI 4–30) mg with placebo
(Table 2). The unadjusted geometric mean reduc-
tion in the vitamin C group was greater than that in
the placebo group by a ratio of 4.37 (95% CI
1.06–18.20, P ¼ 0:04), and after adjustment of this
difference for baseline inhaled corticosteroid dose
the effects remained at borderline statistical
significance (adjusted ratio ¼ 4.03, 95% CI
0.95–17.06, P ¼ 0:06). There was no difference in
corticosteroid reduction between magnesium and
placebo (unadjusted reduction ratio ¼ 1.22, 95% CI
0.28–5.25).
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Table 1 Baseline characteristics of participants.
Total eligible to
enter study
Participants who entered corticosteroid
reduction protocol
Participants
who did not
enter
corticosteroid
reduction
protocol
Vit C Mag Placebo
Demographics
Number 300 29 31 32 208
Male (%) 112 (37%) 14 8 18 72
Mean age (years) [SD] 41 (11) 45 43 41 40
Mean daily
corticosteroid dose (mg)
[SD]
646 (506) 626 593 502 679
Number on high dose
corticosteroid (%)
28 (9) 1 3 1 23
Number on long acting
b-agonists (%)
50 (17) 8 6 5 31
Allergen sensitised (%) 229 (79) 23 22 26 158
Current smokers (%) 12 (4) 0 1 0 11
Mean pack years [SD] 1.3 (2.6) 1.0 1.0 0.6 1.5
Mean dietary vit C (mg)
[SD]
83 (36) 84 82 89 83
Mean dietary
magnesium (mg) [SD]
322 (87) 317 309 350 321
Biological markers
Mean serum mag
(mmol) [SD] n ¼ 79
0.8 (0.07) 0.8 0.8 0.8 0.8
Mean 24 h mag
excretion (mmol) [SD]
n ¼ 74
3.5 (1.9) 3.6 3.4 3.5 3.4
Mean serum vit C
(mmol/L) [SD] n ¼ 79
48.4 (23.3) 50 42 44 50
Baseline measures
Mean FEV1 (L) [SD] 2.8 (0.8) 2.9 2.7 3.0 2.7
Mean FVC (L) [SD] 3.7 (1.0) 3.9 3.5 4.2 3.6
Mean log10 PD20 [SD] 0.28 (0.73) 0.37 0.38 0.35 0.23
am peak flow (L/min)
[SD]
429 (92) 454 423 435 425
pm peak flow (L/min)
[SD]
438 (91) 455 429 441 436
Daily symptom score
[SD]
0.6 (0.7) 0.2 0.6 0.4 0.7
Inhaler use (puffs/day)
[SD]
2.0 (2.5) 1.3 1.9 1.0 2.3
All measurements taken at baseline prior to nutrient supplementation.
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There have been relatively few randomised con-
trolled trials of the potential therapeutic benefits
of vitamin C and magnesium in the control of
asthma, and the present study of 26 weeks ofsupplementation is the longest reported to date.
Our study has demonstrated no clear evidence of
benefit from regular oral magnesium supplements,
but found an effect, at the borderline of statistical
significance, on regular inhaled corticosteroid
requirement in participants allocated to vitamin C.
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Table 2 Mean decrease in inhaled corticosteroid dose in participants (intention to treat analysis).
Group Number of
participants
Geometric mean
decrease in
corticosteroid [mg]
(95% CI)
Reduction ratio
compared to
placeboy
95%CI of reduction
ratio compared to
placeboy
P valuey
Placebo 32 11 (4–30)
Vitamin C 29 49 (18–132) 4.03 0.95–17.06 0.06
Magnesium 31 13 (5–38) 1.03 0.23–4.30 0.97
Using the daily dose of inhaled corticosteroid at the final visit compared to baseline (mg), expressed as dose standardised to
beclomethasone equivalent dose.
yCalculated using multiple linear regression correcting for baseline inhaled corticosteroid dose.
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tion using vitamin C and magnesium supplementa-
tion, any benefit is likely to be small and difficult to
detect in patients with asthma that are already
controlled. That our patients’ asthma was well
controlled is demonstrated by the fact that their
mean baseline peak flow levels were high, and their
average subjective score on a scale from 0 to 5 was
only 0.4. The corticosteroid reduction study was
therefore designed to determine whether this good
level of asthma control could be maintained on a
lower regular dose of inhaled corticosteroids. In
most studies of an experimental treatment the
optimal duration and study population of the
intervention is unknown, and as a consequence of
the paucity of previous longer-term studies of the
therapeutic benefits of vitamin C and magnesium
on asthma control the duration of intervention for
our study was a maximum of 26 weeks, a decision
made due to logistic considerations. Thus we are
unable to exclude the possibility that a different
study design using a longer duration of intervention
or a different study population such as children may
demonstrate a marked benefit of vitamin C or
magnesium supplementation on asthma control.
Another limitation of our study is the reduction in
the power of the study as a consequence of the
lower than anticipated recruitment rate achieved
from those eligible who completed the original 16-
week intervention study; we had expected over 200
to participate when in the event only 92 did.
However, examination of the confidence intervals
around our estimates permits estimation of the size
of any treatment effects. Although we conclude
that our study provides no evidence for a beneficial
effect of magnesium, we are unable to exclude the
possibility that magnesium supplementation may
result in up to a four-fold reduction in steroid dose
demonstrated by the 95% confidence intervals. The
interpretation of the potential therapeutic benefits
of vitamin C supplementation on the requirementfor inhaled corticosteroid is again limited by the
low power of the study, but those who received
vitamin C were able to reduce their inhaled
corticosteroid dosage fourfold more than those
who received placebo, with a lower 95% confidence
interval of 0.95 and a higher 95% confidence
interval of 17 times more than placebo, just outside
the conventional criteria for statistical significance
(P ¼ 0:06). Those who elected to continue in the
study were generally similar to those who did not,
but they had a marginally lower average daily
inhaled baseline corticosteroid dose than partici-
pants in the original trial, particularly in the
placebo group. Adjusting for baseline steroid dose
therefore reduced the size of effect of vitamin C
compared to placebo, but it remained of borderline
statistical significance, suggesting that differential
participation does not explain this effect. Adher-
ence to the supplements, as reported in our original
paper was good.11
While recent work has demonstrated that neb-
ulised magnesium has a significant bronchodilator
effect in acute asthma,14 while intravenous mag-
nesium is of recognised benefit in this patient
group,15 our findings indicate that this beneficial
effect is limited to the context of acute severe
disease. We are not aware of any studies using oral
magnesium supplements in acute asthma, but our
pilot studies suggested that the limited efficiency
of magnesium absorption would limit the applic-
ability of this approach.16
The benefits of vitamin C on asthma control have
however been demonstrated elsewhere, and in
diverse populations such as Nigeria, Mexico and The
Netherlands. In Nigeria, Anah demonstrated a
reduction in asthma attacks in patients with asthma
in the rainy season using 1 g vitamin C over 14
weeks.10 In Mexico City, Romieu and colleagues
have shown a benefit of vitamin C on bronchocon-
striction secondary to ozone in both street workers
(with vitamin E and b-carotene) over an 18-week
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vitamin E) over a 12-week period.18 Similar findings
of a protective effect of vitamin C, in combination
with vitamin E and b-carotene, on ozone-induced
bronchoconstriction have also been reported in
cyclists in The Netherlands.19,20 Thus, our observa-
tion of small decrement in daily inhaled corticos-
teroids after 26 weeks vitamin C supplementation
is, albeit of borderline significance, consistent with
the existing literature.
We conclude therefore that regular oral supple-
mentation for 26 weeks with magnesium has no
significant effect on the requirement for inhaled
corticosteroids in adults with asthma, but that
vitamin C may have a modest corticosteroid sparing
effect equivalent to a decrease in 38 mg beclo-
methasone per day. As the side effects of inhaled
corticosteroids are dose related,21 further ade-
quately powered studies are necessary to deter-
mine whether our findings can be confirmed, and
hence whether patients with asthma should be
recommended to use regular oral vitamin C
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